CDK4 and neoplasm: Interestingly, it has recently been shown that CDK4/6 inhibitors induce an anti-tumor immunogenic response by 4 primary mechanisms: (1) increased antigen presentation in the tumor itself via innate and adaptive immunity, (2) enhanced T-cell activation, (3) suppressed proliferation of immunoresponsive regulatory T cells (Tregs) and (4) induction of a memory T cell phenotype [159, 171–176].